Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study

BACKGROUND: Plexiform neurofibromas (PN) are a manifestation of neurofibromatosis type 1 (NF1) that may cause morbidity and impact health-related quality of life (HRQoL). Selumetinib (ARRY-142886, AZD6244) is an orally available, selective, mitogen-activated protein kinase kinase 1/2 inhibitor appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Suenobu, Souichi, Terashima, Keita, Akiyama, Masaharu, Oguri, Tomoyo, Watanabe, Asako, Sugeno, Masatoshi, Higashimori, Mitsuo, So, Karen, Nishida, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243862/
https://www.ncbi.nlm.nih.gov/pubmed/37287695
http://dx.doi.org/10.1093/noajnl/vdad054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243862/
https://www.ncbi.nlm.nih.gov/pubmed/37287695
http://dx.doi.org/10.1093/noajnl/vdad054

Ejemplares similares